Suppr超能文献

头孢比普对粪肠球菌的时间杀菌及协同作用研究,包括产β-内酰胺酶和耐万古霉素菌株。

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

作者信息

Arias Cesar A, Singh Kavindra V, Panesso Diana, Murray Barbara E

机构信息

University of Texas Medical School, Houston, TX 77030, USA.

出版信息

Antimicrob Agents Chemother. 2007 Jun;51(6):2043-7. doi: 10.1128/AAC.00131-07. Epub 2007 Apr 16.

Abstract

Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against gram-positive cocci, including enterococci. Ceftobiprole MICs were determined for 93 isolates of Enterococcus faecalis (including 16 beta-lactamase [Bla] producers and 17 vancomycin-resistant isolates) by an agar dilution method following the Clinical and Laboratory Standards Institute recommendations. Ceftobiprole MICs were also determined with a high inoculum concentration (10(7) CFU/ml) for a subset of five Bla producers belonging to different previously characterized clones by a broth dilution method. Time-kill and synergism studies (with either streptomycin or gentamicin) were performed with two beta-lactamase-producing isolates (TX0630 and TX5070) and two vancomycin-resistant isolates (TX2484 [VanB] and TX2784 [VanA]). The MICs of ceftobiprole for 50 and 90% of the isolates tested were 0.25 and 1 microg/ml, respectively. All Bla producers and vancomycin-resistant isolates were inhibited by concentrations of </=1 and </=4 microg/ml, respectively, at the standard inoculum concentration. Ceftobiprole MICs at a high inoculum concentration for a subset of five Bla(+) E. faecalis isolates were </=1 microg/ml. Bactericidal activity was observed against four isolates tested at concentrations as low as 1 microg/ml regardless of the production of beta-lactamase or vancomycin resistance. A combination of ceftobiprole (0.5 microg/ml) and streptomycin (25 microg/ml) was synergistic against Bla(+) TX0630 and TX5070. Ceftobiprole (0.5 microg/ml) plus gentamicin (10 microg/ml) was synergistic against VanB isolate TX2484 and showed enhanced killing, but not synergism, against TX2784 (VanA), despite the absence of high-level resistance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E. faecalis, including Bla(+) and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected isolates.

摘要

头孢比普(BAL9141)是一种处于研究阶段的头孢菌素,对革兰氏阳性球菌具有广泛的体外活性,包括肠球菌。按照临床和实验室标准协会的建议,采用琼脂稀释法对93株粪肠球菌(包括16株β-内酰胺酶[Bla]产生菌和17株耐万古霉素菌株)测定了头孢比普的最低抑菌浓度(MIC)。还通过肉汤稀释法对属于不同先前已鉴定克隆的5株Bla产生菌的一个子集,在高接种浓度(10⁷CFU/ml)下测定了头孢比普的MIC。对两株产β-内酰胺酶菌株(TX0630和TX5070)以及两株耐万古霉素菌株(TX2484[VanB]和TX2784[VanA])进行了时间杀菌和协同作用研究(与链霉素或庆大霉素联合)。头孢比普对50%和90%受试菌株的MIC分别为0.25和1μg/ml。在标准接种浓度下,所有Bla产生菌和耐万古霉素菌株分别被≤1和≤4μg/ml的浓度所抑制。对5株Bla(+)粪肠球菌菌株的一个子集在高接种浓度下的头孢比普MIC≤1μg/ml。无论是否产生β-内酰胺酶或耐万古霉素,在低至1μg/ml的浓度下对4株受试菌株均观察到杀菌活性。头孢比普(0.5μg/ml)与链霉素(25μg/ml)联合对Bla(+)的TX0630和TX5070具有协同作用。头孢比普(0.5μg/ml)加庆大霉素(10μg/ml)对VanB菌株TX2484具有协同作用,对TX2784(VanA)显示出增强的杀菌作用,但无协同作用,尽管对庆大霉素不存在高水平耐药。总之,头孢比普对粪肠球菌,包括Bla(+)和耐万古霉素菌株,表现出良好的体外活性,并与氨基糖苷类药物对选定菌株表现出协同作用。

相似文献

2
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
J Antimicrob Chemother. 2007 Sep;60(3):594-8. doi: 10.1093/jac/dkm237. Epub 2007 Jul 2.
7
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. doi: 10.1111/j.1469-0691.2007.01722.x.
8

引用本文的文献

4
Treatment of Infective Endocarditis: A Continuing Challenge.
Antibiotics (Basel). 2023 Apr 4;12(4):704. doi: 10.3390/antibiotics12040704.
7
Ceftobiprole for the treatment of pneumonia: a European perspective.
Drug Des Devel Ther. 2015 Aug 18;9:4565-72. doi: 10.2147/DDDT.S56616. eCollection 2015.
9
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Antimicrob Agents Chemother. 2014 Jul;58(7):3882-8. doi: 10.1128/AAC.02465-14. Epub 2014 Apr 28.
10
Intrinsic and acquired resistance mechanisms in enterococcus.
Virulence. 2012 Aug 15;3(5):421-33. doi: 10.4161/viru.21282.

本文引用的文献

1
In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
Antimicrob Agents Chemother. 2006 Nov;50(11):3959-62. doi: 10.1128/AAC.00722-06. Epub 2006 Sep 18.
4
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Diagn Microbiol Infect Dis. 2006 Aug;55(4):333-6. doi: 10.1016/j.diagmicrobio.2006.01.029. Epub 2006 May 2.
7
Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Antimicrob Agents Chemother. 2004 Jul;48(7):2576-80. doi: 10.1128/AAC.48.7.2576-2580.2004.
8
Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Antimicrob Agents Chemother. 2004 Jul;48(7):2570-5. doi: 10.1128/AAC.48.7.2570-2575.2004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验